Halozyme Therapeutics' (HALO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO - Free Report) in a research note published on Thursday,Benzinga reports.

A number of other research analysts have also issued reports on HALO. Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded up $0.46 on Thursday, reaching $61.44. 2,090,909 shares of the company's stock were exchanged, compared to its average volume of 1,311,262. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The business's 50-day moving average is $55.70 and its two-hundred day moving average is $54.68. The firm has a market capitalization of $7.57 billion, a price-to-earnings ratio of 17.91, a PEG ratio of 0.42 and a beta of 1.32.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the sale, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock valued at $1,754,451 in the last ninety days. 2.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $29,000. CBIZ Investment Advisory Services LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics in the fourth quarter valued at $69,000. Finally, Parkside Financial Bank & Trust grew its position in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.